Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
November 8, 2022Journal of the American Heart AssociationOpen Access

Trends in Oral Anticoagulant Use Among 436 864 Patients With Atrial Fibrillation in Community Practice, 2011 to 2020

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Guidelines recommend DOACs over warfarin for stroke prevention in nonvalvular AF, but changes in DOAC use over the past decade have not been well described.

Population

436 864 adults with AF and a CHA2DS2-VASc score >=2 across 88 US health systems

Comparison

DOACs vs warfarin use over time and across demographic and health-system levels

Design

Electronic health record-based trend analysis

Authors

ANAnn Marie NávarAKAhmed A. KolkailahRORobert Overton

Discussion

Loading...

Member takes

Overview

Anticoagulation rates rose modestly with DOAC adoption but remain incomplete in AF; extends temporal trends yet leaves open reasons for persistent gaps.

Structured PICO

P
Population
436,864 adults with atrial fibrillation (AF) and an elevated stroke risk (CHA2DS2-VASc score ≥2), median age 78 years, 52.1% men, from 88 health systems in the United States.
I
Intervention
Direct oral anticoagulants (DOACs)
C
Comparator
Warfarin or no anticoagulation
O
Outcome
Trends in the use of DOACs and warfarin from 2011 to 2020

Over the past decade, DOACs have largely replaced warfarin for stroke prevention in high-risk AF patients, but significant gaps remain as one in three patients is still not on any anticoagulant.

Cite This Study

Návar et al. (2022) studied this question.

synapsesocial.com/papers/69dccbf72e182f147e1332d5https://doi.org/10.1161/jaha.122.026723
View Full Paper
Ask AI
Bookmark
Share